Toby Pillinger

Academic Clinical Lecturer

King’s College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Toby Pillinger is an Academic Clinical Lecturer at King's College London, UK. His research primarily focuses on the impact of glucagon-like peptide-1 receptor agonists on cognitive and mental health disorders, as well as the biological alterations related to psychosis. He is also involved in developing international guidelines for the treatment of schizophrenia and studying the effects of antipsychotic medications on physical health and weight management.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (25)

James Stone

University of Sussex

UNITED KINGDOM

Toby Pillinger

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders

INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia

Psychotropic Taxonomies: Constructing a Therapeutic Framework for Psychiatry

Do biological alterations precede the onset of psychosis? A systematic review and meta-analysis of immune, cardiometabolic, prolactin and HPA axis alterations in clinical high-risk for psychosis

Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis

Impact of Early Antipsychotic Prescription Choice on Weight Gain in the First 5 Years of Psychotic Illness: a Retrospective Cohort Study

International Guidelines for the Algorithmic Treatment of Schizophrenia (INTEGRATE) – Authors' reply

Physical illness in schizophrenia and the role of tolerability in antipsychotic selection: an expert consensus with a focus on cariprazine

Metformin for the Prevention of Antipsychotic-Induced Weight Gain

Comparative physiological effects of antipsychotic drugs in children and young people: a network meta-analysis

Effect of polygenic risk for schizophrenia on cardiac structure and function: a UK Biobank observational study.

Data-Driven Taxonomy for Antipsychotic Medication: A New Classification System

Prolactin and morning cortisol concentrations in antipsychotic naïve first episode psychosis: A systematic review and meta-analysis.

Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends

Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study

The association between N-methyl-d-aspartate receptor availability and glutamate levels

Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of <sup>18</sup>FDG-PET studies in schizophrenia.

Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis.

Immunopsychiatry in 2021: premise to promise, and back again.

Adipose tissue dysfunction, inflammation, and insulin resistance: alternative pathways to cardiac remodelling in schizophrenia. A multimodal, case–control study

Collaborators (25)

James Stone

Stefan Kaiser

Colm McGinnity

Matthew Nour

Brian ODonoghue

Walter Cullen

Paul McCrone

James MacCabe

Fiona Gaughran

Daniel Alonso-Alconada

Valentina Mancini

Sameer Jauhar

Chaomei Chen

Rachel Upthegrove

Emanuele Felice Osimo

Alexander Hammers

David Lythgoe

Joel Dunn

Stefan Leucht

Declan P O’Regan

Enrico D'Ambrosio

Mattia Veronese

Atheeshaan Arumuham

Robert McCutcheon

Antonio de Marvao

Make your next move.